AGP Executive Report
Last update: 3 hours agoFDA & Peptide Safety: A Public Citizen investigation says the FDA has largely let the “peptide craze” spread, flagging retatrutide use outside clinical trials and linking the unapproved weight-loss drug to hospitalizations. Diabetes Drug Watch: Novo Nordisk’s CagriSema (cagrilintide + semaglutide) showed stronger weight and A1c results in phase 3 trials for type 2 diabetes, including people on insulin. Massachusetts Health Policy: Massachusetts opioid overdose deaths fell below 1,000 for the first year since 2013, while MassHealth moves to end a homeless health care program serving thousands statewide. Workforce & Care Access: A federal judge in Boston struck down Trump’s $100,000 H-1B fee as an unlawful tax, a ruling that states say could otherwise raise costs for universities and healthcare training. Public Health Alerts: Health officials warned of rising norovirus in Boston-area facilities tied to summer cruise season and restaurant/camp exposures. Local Health & Community: Dana-Farber received a historic $50M Yawkey Foundation grant, supporting cancer care and research.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![[Latest] Global Gastrointestinal Endoscopy Devices Market Size/Share Worth USD 19.6 Billion by 2035 at a 5.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)](https://ml.globenewswire.com/Resource/Download/af9c6fb4-2b61-4367-852e-7237ba1d9bc4/north-america-gastrointestinal-endoscopy-devices-market-size-2025-to-2035-usd-billion-.png)
